Skip to main content

Table 1 Baseline (mean ± standard deviation) and on-treatment clinical and biochemical attributes

From: NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

 

overall

males

females

number

101

61

40

age (years)

55.6 ± 11.9

54.0 ± 10.7

58.0 ± 13.3

days on treatment

83.8 ± 60.6

90.1 ± 67.6

74.5 ± 47.9

percent on statin

69.3

78.7

55.0

plasma lipids and lipoproteins (mmol/L)

   baseline

   

cholesterol

   

- total

6.57 ± 1.43

6.33 ± 1.54

6.93 ± 1.18

- LDL

4.51 ± 1.40

4.35 ± 1.53

4.72 ± 1.18

- HDL

1.18 ± 0.30

1.15 ± 0.29

1.22 ± 0.31

triglycerides

2.50 ± 2.36

2.63 ± 2.86

2.32 ± 1.33

   on-treatment

   

cholesterol

   

- total

5.41 ± 1.32

5.10 ± 1.21

5.88 ± 1.35

- LDL

3.35 ± 1.15

3.21 ± 1.11

3.56 ± 1.19

- HDL

1.23 ± 0.45

1.16 ± 0.33

1.33 ± 0.60

triglycerides

2.25 ± 1.91

2.24 ± 2.12

2.25 ± 1.57

  1. abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein;